Cardiovascular Systems Added to Russell 3000® Index

ST. PAUL, Minn.--(Business Wire)--
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company
developing and commercializing innovative interventional treatment systems for
vascular disease, has been added to the Russell 3000 Index, which measures the
performance of the 3,000 largest U.S. companies based on total market
capitalization. The Russell Investment Group recently reconstituted its indexes,
and Russell 3000 membership went into effect June 26, 2009 and will remain in
place for one year.

"Inclusion in the new Russell 3000 Index recognizes CSI`s February 2009 debut as
a publicly traded company and will enhance our company`s visibility among
investors," said David L. Martin, CSI president and chief executive officer.
"More than 12 million patients in the United States alone suffer from peripheral
arterial disease, and most current therapies provide poor clinical and economic
outcomes. The Diamondback 360o procedure is safe, minimally invasive and offers
dramatic advantages in recovery and cost to patients, their families and
healthcare providers. As a result, nearly 500 hospitals have adopted our
Diamondback 360o system since the September 2007 launch."

The Russell 3000 Index is constructed to provide a comprehensive, unbiased and
stable barometer of the broad market and is completely reconstituted annually to
ensure new and growing equities are reflected.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc. is a medical device company focused on developing
and commercializing interventional treatment systems for vascular disease.
Between 8 and 12 million Americans suffer from peripheral arterial disease
(PAD), which is caused by the accumulation of plaque in leg or foot arteries,
reducing blood flow and leading to leg pain, and eventually tissue loss and
amputation. The company`s Diamondback 360° Peripheral Arterial System is capable
of treating a broad range of plaque types both above and below the knee, and
addresses many of the limitations associated with existing treatment
alternatives. In August 2007, the U.S. FDA granted 510(k) clearance for the use
of the Diamondback 360° as a therapy for PAD (peripheral arterial disease), and
CSI commenced a U.S. product launch in September 2007. The Diamondback 360°
system has been adopted by nearly 500 hospitals across the United States. For
more information visit the company`s Web site at www.csi360.com.

For Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
investorrelations@csi360.com
or
Padilla Speer Beardsley:
Marian Briggs, 612-455-1742
mbriggs@psbpr.com
or
Nancy A. Johnson, 612-455-1745
njohnson@psbpr.com

Copyright Business Wire 2009